Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 8/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27308664 | 1.00 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL2913004 | 1.00 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL2913008 | 1.00 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL17812945 | 1.00 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL30743015 | 1.00 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL21598852 | 0.88 | CHRM2 (0.44) | NR1H2CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL11099691 | 0.86 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL2683392 | 0.86 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL5155598 | 0.86 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL15909556 | 0.86 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022197641-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-AMINE DERIVATIVES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS AND/OR INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | RAPT THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-2010506-B1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-2010506-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007122103-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | NR1H2 3017/4885CHRM2 4852/4885CHRM1 4811/4885 |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, MCL1, DTYMK | NR1H2 3017/4885CHRM2 4852/4885CHRM1 4811/4885 |
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | NR1H2 188/4885CHRM2 33/4885CHRM1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.